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Abstract
Breath testing has the potential to benefit the medical field as a cost-effective, non-invasive diagnostic
tool for diseases of the lung and beyond. With growing evidence of clinical worth, standardization of
methods, and new sensor and detection technologies the stage is set for breath testing to gain
considerable attention and wider application in upcoming years.
Introduction and context
With each breath exhaled thousands of molecules are
expelled, providing a window into the physiological
state of the body. The utilization of breath as a medical
test has been reported for centuries as demonstrated by
Hippocrates in his description of fetor oris and fetor
hepaticus in his treatise on breath aroma and disease [1].
Even in modern times clinicians have noted distinct
changes in the breath odor of patients with specific
diseases such as diabetes, renal failure, and hepatic
diseases [2-4]. However, it was Linus Pauling’s milestone
discovery of 250 unique substances present in exhaled
breath that offered promising insight into breath testing
[5]. Since this discovery, breath analysis has rapidly
evolved as a new frontier in medical testing for disease
states in the lung and beyond [1]. Breath analysis is now
used clinically to monitor asthma, diagnose transplant
organ rejection, diagnose Helicobacter pylori infection,
detect blood alcohol concentration, and monitor breath
gases during anesthesia, mechanical ventilation, and
respiration, among numerous other applications [1,6,7].
Recent advances
Breath analysis may offer a relatively inexpensive, rapid,
and non-invasive method for detecting a variety of
diseases. With recent advancements in mass spectrometry
(MS) and gas chromatography MS (GC-MS), it is possible
to identify thousands of unique substances, such as
volatile organic compounds (VOCs) and elemental
gases, in the breath [8]. Improved technologies such as
selected-ion flow-tube MS (SIFT-MS), multi-capillary
column ion mobility MS (MCC-IMS), and proton transfer
reaction MS (PTR-MS) have provided real time, precise
identification of trace gases in human breath in the parts
per trillion range [9-11]. On the other hand, unlike
traditionalquantitativebreathanalysis,theelectronicnose
is essentially trained to recognize odor patterns using an
array of gas sensors. The electronic nose has shown
accuracy in the detection of lung cancer, pneumonia, and
asthmawithspecificitiesandsensitivitiesrangingfrom74-
98%, as well as in the discrimination between diseases
suchaschronicobstructivepulmonarydiseaseandasthma
[12-15]. Table 1 provides a selected list of the growing
number of technologies being applied to breath testing.
More recent technological advancements in breath analy-
sis have moved beyond measuring volatiles in the gas
phase into measurement ofsemivolatilesand compounds
dissolved in aerosolized droplets in exhaled breath
condensate (EBC) and in exhaled breath vapor (EBV).
AerosolizeddropletsinEBCcanbecapturedbyavarietyof
methods and analyzed for a wide range of biomarkers,
such as metabolic end products, proteins, cytokines, and
chemokines, with expanding possibilities [16,17]. With
3000 volatile compounds identifiable using EBC and
twice the volatile metabolite concentration compared to
traditional breath gas analysis, this application has the
potential to provide superior information about
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sampling has also yielded promising results as a new
breath sampling method. EBV sampling pre-concentrates
breath samples using a solid-phase microextraction fiber
inserted into a modified RTube™, a common device also
used in EBC sampling. This procedure provides the
potential advantages of faster breath sampling and
analysis, increased portability, minimal user training, use
in contaminated environments, and no requirement for a
power source. EBV sampling may yield additional
compounds not detected in EBC and may provide greater
sensitivity as a sampling method, expanding the spectrum
of breath sampling [19].
Implications for clinical practice
The science of breath analysis is rapidly expanding, the
technology is improving, and several new applications
have been developed or are under commercial develop-
ment. A major breakthrough over the past decade has
been the increase in breath-based tests approved by the
US Food and Drug Administration (FDA). Devices
measuring common breath gases: oxygen, nitrogen,
water vapor, and carbon dioxide in patient respiratory
monitoring have served as a platform for technological
growth in clinical breath testing applications. In parti-
cular, earlier devices, such as those providing the
detection of blood alcohol concentration, H. pylori
infection, lactose intolerance, and airway monitoring
by end-tidal carbon dioxide, have demonstrated clinical
benefits as well as diagnostic success in clinical breath
testing. Table 2 provides a selected list of the breath-
based tests currently approved by the FDA.
One recent landmark in clinical breath testing occurred
in 2003 when the FDA approved the first device that
measures the fraction of exhaled nitric oxide (FENO) for
asthma monitoring. The desktop NIOX® (currently
NIOX® FLEX) was followed by a handheld NIOX®
MINO device (both by Aerocrine, Inc., Solna, Sweden)
that received FDA clearance in 2008. Advantages
provided by FENO monitoring devices include its non-
invasive nature, ease of repeat measurements, and use in
adult and child populations with severe airflow obstruc-
tion where other techniques would be difficult or
impossible to perform [20]. FDA approval of these
devices has largely been attributed to the standardization
Table 1. Current breath-based test technologies
Spectrometry Gas chromatography Other
Mid-infrared absorption spectroscopy Automated thermal desorption gas chromatography
mass spectrometry (ATD-GC-MS)
Chemiluminescense
Multi pass cell-laser absorption spectroscopy Gas chromatography flame ionization
detection (GC-FID)
Electrochemical cell sensor technology
Tunable diode laser absorption spectroscopy (TDLAS) Gas chromatrography mass spectrometry (GC-MS) Gas sensor array technology
Cavity ring-down spectroscopy (CRDS) Photoionization detection gas chromatography Nanosensor technology
Cavity leak-out spectroscopy (CALOS) Solid phase microextraction gas chromatography mass
spectrometry (SPME-GC-MS)
Infrared and para-magnetic sensors
Cavity enhanced optical frequency comb spectroscopy Gas chromatography time of flight mass spectrometry
(GC-TOF-MS)
Calorimetry
Integrated cavity output spectroscopy (ICOS) Gas chromatography differential mobility spectrometry
(GC-DMS)
Sol-gel sensor technology
Laser magnetic resonance spectroscopy (LMRS) Gas chromatography ion mobility mass spectrometry
(GC-IMS-MS)
Laser based sensor technology
Laser photoacoustic spectroscopy Gas chromatography/Fourier transform ion cyclotron
resonance mass spectrometry (GC/FT-ICR-MS)
Faraday-LMRS Gas-liquid partition chromatography (GLPC)
Selected ion flow tube mass spectrometry (SIFT-MS) Gas chromatography electrolyzer-powered flame
ionization detector (GC-EFID)
Proton transfer reaction mass spectrometry (PTR-MS)
Faraday modulation spectroscopy
Ion trap (2D) and (3D) mass spectrometry
Time of flight mass spectrometry (TOF-MS)
Isotope ratio mass spectrometry (IR-MS)
Multi-capillary column ion mobility mass spectrometry
(MCC-IMS)
High sensitivity (hs)-PTR-MS
Matrix assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF-MS)
Proton transfer reaction time of flight mass
spectrometry (PTR-TOF-MS)
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analysis [21]. In order for this simple yet powerful tool to
achieve its potential, we need to further understand the
roles that FENO and similar biomarkers of disease play in
different clinical settings and across populations, and
their specific functions in disease.
A recent clinical application of breath testing has been in
the diagnosis of lung cancer. Currently, clinicians rely on
relatively expensive and invasive diagnostic tests, such as
computed tomography exams, chest radiography, spu-
tum analysis, and lung biopsies, which remain largely
ineffective in early stage lung cancer diagnosis. Research-
ers have demonstrated success using trained dogs in the
breath diagnosis of both early and late stage lung cancers
with sensitivities and specificities approaching 99%,
providing promise for future lung cancer breath tests
[22]. Breath testing may provide a promising alternative
diagnostic tool for lung cancer as evidenced by numer-
ous studies with specificities and sensitivities ranging
from 71-94% [14,23-28]. However, in order to be useful
as an upfront screening test for high-risk populations, as
a tool to evaluate pulmonary nodules, or as a diagnostic
test for lung cancer, a breath test should be at least 90-
95% sensitive and specific [29].
As the field of breath research has developed over the
past decade, the need for standardization in sampling
has grown. Attempts at sampling only critical portions
of exhaled breath have proven successful by using end-
tidal sampling, as evidenced by finding VOC concentra-
tions most reflective of compounds dissolved in the
blood [30]. End-tidal sampling (collecting breath only
at the end of exhalation) has shown success over mixed
expiratory sampling (collecting the entire exhaled
breath) because samples are less likely to be diluted
by mixing with dead space volume (inspired air not
taking place in gas exchange) and ambient air. A useful
application is buffered end-tidal on-line sampling,
which measures VOC breath concentrations over a
large mass range quickly and uses multiple MS
technologies, such as SIFT-MS and PTR-MS, for breath
analysis [31]. It is also promising because it uses on-line
sampling (the sampling device is connected to the
analytical device) versus less accurate off-line sampling
(the sample is collected and later brought to the
analytical device using reservoirs such as Tedlar®
bags). Device calibration and validation have helped
by accounting for exogenous VOCs and ambient air
contamination in the sampling environment [19]. Since
detection of many VOCs occurs at the parts per billion
and parts per trillion levels, it is essential to control for
exogenous sources of VOCs because ingestion of certain
foods, medications, gut bacterial flora, and exposure to
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F1000 Medicine Reports 2010, 2:56 http://f1000.com/reports/medicine/content/2/56chemicals and pollution, amongst many other things,
will alter VOCs in exhaled breath [32]. It is important
for researchers to consider the change in the concentra-
tion of several VOCs in disease states as well as the
utility of ranking systems for VOC predictability and
new methods for accounting for ambient VOC sources,
such as calculating alveolar gradients [8,28]. Despite
receiving considerable attention in recent years, issues
with standardization have been a major limitation of
clinical breath testing. This has been evidenced by
difficulties in establishing baseline VOC concentrations
and the wide range of results represented in the
literature for VOC concentrations in disease. Thus, it is
necessary in the future to search for innovative methods
for breath research.
There are numerous potential advantages for breath
analysis as a clinical test. The method is non-invasive
(the sample is relatively easy and painless to acquire), the
sample is likely to be rich with information (a single test
can scan for signatures of many abnormalities or markers
of disease), it has the potential for low cost, and lends
itself to easy administration. The field of breath testing
has grown tremendously in recent years and with
evolving technologies in sampling, sensor design,
standardization, and analytical methods breath analysis
has the potential to clinically benefit individuals on a
global scale in the future.
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